|Summary sheet: 5-MeO-DiBF|
|Routes of Administration|
5-Methoxy-N,N-diisopropylbenzofuranethylamine (also known as 5-MeO-DiBF) is a novel psychedelic substance of the benzofuran class that produces psychedelic and stimulating effects when administered. It is related in structure to 5-MeO-DiPT.
This compound has little to no history of human usage prior to its September 2015 release on the online research chemical market.
Very little is known about the pharmacological properties, metabolism, and toxicity of 5-MeO-DiBF. Due to its extreme novelty and unknown toxicity profile, it is highly advised that one use harm reduction practices if using this substance.
5-MeO-DiBF, or 5-methoxy-N,N-diisopropylbenzofuranethylamine, is a synthetic heterocyclic alkaloid molecule of the benzofuran class. Benzofuran is a bicyclic structure formed by the fusion of a benzene ring and a furan ring, a five member aromatic ring containing an oxygen substituent.
5-MeO-DiBF is composed of a benzofuran group attached at R3 to an amino group via an ethyl side chain. It is substituted at R5 of the benzofuran heterocycle with a methoxy (MeO) functional group CH3O−; it also contains two isopropyl chains bound to the terminal amine RN of its tryptamine backbone (DiBF).
The benzofuran group of 5-MeO-DiBF is closely related in structure to the indole found in tryptamines; benzofuran contains an oxygen group at the same location that indole contains a nitrogen. As such, 5-MeO-DiBF is closely related in structure to the psychedelic tryptamine 5-MeO-DiPT. 5-MeO-DiBF is the benzofuran analogue of 5-MeO-DiPT.
5-MeO-DiBF likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from its efficacy at the 5-HT1A and 5-HT2 family of serotonin receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
Disclaimer: The effects listed below are cited from the Subjective Effect Index (SEI), which relies on assorted anecdotal reports and the personal experiences of PsychonautWiki contributors. As a result, they should be taken with a healthy amount of skepticism. It is worth noting that these effects will not necessarily occur in a consistent or reliable manner, although higher doses (common+) are more likely to induce the full spectrum of reported effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Spontaneous physical sensations - The "body high" of 5-MeO-DiBF can be described as a motionless, constant, sharp and all-encompassing tingling sensation. This maintains a consistent presence that steadily rises with the come up and hits its limit once the peak has been reached.
- Increased heart rate
- Muscle spasms
- Nausea - This effect is particularly mild compared to other psychedelics.
- Perception of bodily lightness
- Pupil dilation
- Tactile enhancement
- Temperature regulation suppression
- The head space of 5-MeO-DiBF is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high doses. The total sum of these cognitive components (regardless of the setting) generally includes:
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational 5-MeO-DiBF use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because 5-MeO-DiBF is a research chemical with very little history of human usage.
Anecdotal reports from those who have tried 5-MeO-DiBF suggest that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this substance.
Tolerance and addiction potential
5-MeO-DiBF is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of 5-MeO-DiBF are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 5-MeO-DiBF presents cross-tolerance with all psychedelics, meaning that after the consumption of 5-MeO-DiBF all psychedelics will have a reduced effect.
Although many psychoactive substances are reasonably safe to use on their own, they can quickly become dangerous or even life-threatening when combined with other substances. The list below includes some known dangerous combinations (although it cannot be guaranteed to include all of them). Independent research (e.g. Google, DuckDuckGo) should always be conducted to ensure that a combination of two or more substances is safe to consume. Some interactions listed have been sourced from TripSit.
- Lithium - Lithium is commonly prescribed in the treatment of bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
- Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
- Stimulants (Amphetamine, cocaine, methylphenidate, ...) - Stimulants affect many parts of the brain and alter dopaminergic function. Combined with psychedelics, stimulation can turn into severe anxiety, panic, thought loops, and paranoia. This interaction may result in an elevated risk of mania and psychosis.
- Tramadol - Tramadol lowers the seizure threshold and psychedelics may act as triggers for seizures in susceptible individuals.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
5-MeO-DiBF is currently thought to be a legal grey area substace in many parts of the world. However, although it is easily accessible through the use of online research chemical vendors, this does not guarantee anyone to be immune from legal prosecution should they be found in possession of this substance as the legality is likely to vary from country to country.
- Germany: 5-MeO-DiBF is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
- United Kingdom: It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- The Characterization of 2-(5-Methoxy-1-benzofuran-3-yl)-N,N-dimethylethanamine (5-MeO-BFE) and Differentiation from its N-Ethyl Analog | http://www.dea.gov/pr/microgram-journals/2012/mj9-1_39-45.pdf
- Benzofuran bioisosteres of hallucinogenic tryptamines (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/1534585
- Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/2139186
- Talaie, H.; Panahandeh, R.; Fayaznouri, M. R.; Asadi, Z.; Abdollahi, M. (2009). "Dose-independent occurrence of seizure with tramadol". Journal of Medical Toxicology. 5 (2): 63–67. doi:10.1007/BF03161089. ISSN 1556-9039.
- "Gesetz zur Bekämpfung der Verbreitung neuer psychoaktiver Stoffe" (PDF) (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019.
- "Anlage NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
- "§ 4 NpSG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019.
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted